Please read this page before participating in this activity. At the bottom of the page, select “I have read these instructions and understand them,” and then click “Begin Activity.”


Overview

Archive, CME credit no longer available
Release Date: June 23, 2010
Expiration Date: June 24, 2011

This activity consists of audio and visual recording of 6 live presentations. To receive CME credit, please read the overview and follow the link to the presentation.

To view presentation, the learner should click on a presentation title. The Webcast will open in a separate window. The learner may view as many presentations in this activity as he/she chooses. Learner agrees that slides are for webcast viewing only. He or she will not copy, alter, or change these Webcast presentations in any way.

Once 1 or more presentations have been reviewed, learners may link to the CME evaluation from a link at the top of the main index of presentations. This is required for credit. Instructions for the evaluation are found on that page.


Needs and Objectives

Upon completion of this activity, learners will be able to:

• Design antiretroviral strategies that consider current data on:
  
  • Interpreting resistance test results
  • Managing treatment failure
  • Initiating therapy
  • Concurrent opportunistic infections
• Describe current data on investigational hepatitis C virus drugs as they impact the potential for treatment
• Develop practical plans for improving patient retention in care
• Formulate practical management strategies for HIV and hepatitis C virus coinfection
  

CME Credit

The International AIDS Society–USA is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The International AIDS Society–USA designates this educational activity for a maximum of 4.5 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Physicians who claimed CME credit for attending the live CME course on which this activity is based may not claim credit for participating in this activity.


Intended Audience

This online CME activity is designed for physicians and other clinical decision makers who are actively involved in the medical care of people with HIV/AIDS, specifically those who:

• Have a solid, working knowledge of HIV disease management
• Provide comprehensive or specialty care for patients with HIV/AIDS
• Are currently active in HIV/AIDS research

This activity is also relevant to nurse practitioners, physician assistants, nurses, and other health professionals who provide care to people with HIV disease.


Course Faculty

Chairs

Henry Masur, MD
Course Chair
Clinical Professor of Medicine
George Washington University School of Medicine
Washington, DC

Michael S. Saag, MD
Course Vice-Chair
Member, Board of Directors (Volunteer)
International AIDS Society-USA
Professor of Medicine
Jim Straley Chair in AIDS Research
Director, Center for AIDS Research
University of Alabama at Birmingham
Birmingham, Alabama

Speakers

Joel E. Gallant, MD, MPH
Member, Board of Directors (Volunteer)
International AIDS Society-USA
Professor of Medicine and Epidemiology
Associate Director, Johns Hopkins AIDS Service
Johns Hopkins University School of Medicine
Baltimore, Maryland

Michael J. Mugavero, MD, MHSc
Assistant Professor of Medicine
University of Alabama at Birmingham
Birmingham, Alabama

Susanna Naggie, MD
Assistant Professor
Duke University School of Medicine
Durham Veterans Affairs Medical Center
Durham, North Carolina

Mark S. Sulkowski, MD
Associate Professor of Medicine
Johns Hopkins University School of Medicine
Baltimore, Maryland

Disclosure of Financial Affiliations

In the interest of maintaining the independence of its continuing medical education (CME) activities, and in accordance with the policies of the Accreditation Council for Continuing Medical Education, the International AIDS Society-USA requires all persons with control of content (ie; faculty, IAS-USA Board members, and program staff) to disclose any financial relationships that they (or their spouses or partners) have had with commercial companies within the past 12 months of the date of this Web-based CME conference. Any conflicts of interest of those parties are resolved prior to the education activity being delivered.

IAS-USA Board of Directors

Constance A. Benson, MD
Dr Benson has received research grants awarded to the University of California San Diego from Gilead Sciences, Inc. She has served on scientific advisory boards for GlaxoSmithKline, ViiV Healthcare, and Merck & Co, Inc, and has chaired a data and safety monitoring board for Achillion Pharmaceuticals, Inc. (Updated 4/08/10)

Judith S. Currier, MD
Dr Currier has received research grants awarded to the University of California Los Angeles from Merck & Co, Inc, and Schering-Plough Corp. (Updated 05/11/10)

Carlos del Rio, MD
Dr del Rio has received research grants awarded to Emory University from Merck & Co, Inc, Schering-Plough Corp, and Sanofi Pasteur. He served as a consultant to, or received honoraria from Bristol-Myers Squibb, Merck & Co, Inc, and Janssen-Cilag. (Updated 05/07/10)

Joel E. Gallant, MD, MPH
Dr Gallant has served as a consultant to Abbott Laboratories. He has been a member of data and safety monitoring boards and endpoint adjudication committees for Gilead Sciences, Inc, and Sangamo Biosciences, Inc. He has been a member of scientific or clinical advisory boards for Bristol-Myers Squibb, Gilead Sciences, Inc, Merck-Serono, and Tibotec Therapeutics. Johns Hopkins University has been the recipient of research grants or contracts from Gilead Sciences for research conducted by Dr Gallant. (Updated 06/05/10)

Roy M. Gulick, MD, MPH
Dr Gulick has served as a consultant to Bristol-Myers Squibb, Gilead Sciences, Inc, and Virostatics and as an investigator for research study grants (to Weill Cornell) from Pfizer Inc, Schering-Plough Corp, Tibotec Therapeutics, and Wyeth. (Updated 03/13/10)

Donna M. Jacobsen
Ms Jacobsen has no relevant financial affiliations to disclose. (Updated 04/12/10)

Douglas D. Richman, MD
Dr Richman has been a consultant to Biota, Bristol-Myers Squibb, CHIMERx, Gen-Probe, Inc, Gilead Sciences, Inc, Idenix Pharmaceuticals, Inc, Merck & Co, Inc, Monogram Biosciences, Myriad Genetics, and Theraclone Sciences. He has been on an endpoint adjudication committee for Schering-Plough Corp and has been the recipient of research grants or contracts from Merck & Co, Inc. Dr Richman has been a stock options holder of CHIMERx and Idenix Pharmaceuticals, Inc, and a stock shareholder of Monogram Biosciences, Inc. (Updated 03/16/10)

Michael S. Saag, MD
Dr Saag has received grants and research support from and has been a scientific advisor to Adrea Biosciences, Inc, Avexa, Ltd, Boehringer Ingelheim Pharmaceuticals, Inc, Bristol-Myers Squibb, Gilead Sciences, Inc, GlaxoSmithKline, Merck & Co, Inc, Monogram Biosciences, Inc, Pfizer Inc, Progenics Pharmaceuticals, Inc, Tibotec Therapeutics, and Tobira Therapeutics. He has received honoraria from Merck & Co, Inc, Pain Therapeutics, Inc, and Pfizer, Inc. (Updated 06/06/10)

Robert T. Schooley, MD
Dr Schooley has served as a consultant to Achillion Pharmaceuticals, Inc, Gilead Sciences, Inc, GlaxoSmithKline, Inhibitex, Inc, Johnson and Johnson, LabCorp, and Merck & Co, Inc. He has stock options for Achillion Pharmaceuticals, Inc. (Updated 05/10/10)

Paul A. Volberding, MD
Dr Volberding has served on data and safety monitoring boards for Merck & Co, Inc, and TaiMed Biologics, and on an endpoint adjudication committee for Schering-Plough Corp. He has provided paid legal consultation for Stanford University and expert testimony for commercial firms. He has served on scientific or clinical advisory boards for Bristol-Myers Squibb, Gilead Sciences, Inc, GlaxoSmithKline, Pfizer Inc, and Tobira Therapeutics and he has been the recipient of service grants for, or held contracts from, GlaxoSmithKline Italy. (Updated 04/07/10)

Course Faculty and Staff

Below are the disclosures of financial relationships of the faculty and program staff of this Web-based CME conference.

Dr Gallant has served as a consultant to Abbott Laboratories. He has been a member of data and safety monitoring boards and endpoint adjudication committees for Gilead Sciences, Inc, and Sangamo Biosciences, Inc. He has been a member of scientific or clinical advisory boards for Bristol-Myers Squibb, Gilead Sciences, Inc, Merck-Serono, and Tibotec Therapeutics. Johns Hopkins University has been the recipient of research grants or contracts from Gilead Sciences for research conducted by Dr Gallant. (Updated 06/05/10)

Dr Masur has no relevant financial affiliations to disclose. (Updated 06/08/10)

Dr Mugavero has received grants and research support from Bristol-Myers Squibb, Pfizer Inc, and Tibotec Therapeutics. He served as a consultant to Bristol-Myers Squibb and Gilead Sciences, Inc. (Updated 03/17/10)

Dr Naggie has no relevant financial affiliations to disclose. (Updated 06/08/10)

Dr Saag has received grants and research support from and has been a scientific advisor to Adrea Biosciences, Inc, Avexa, Ltd, Boehringer Ingelheim Pharmaceuticals, Inc, Bristol-Myers Squibb, Gilead Sciences, Inc, GlaxoSmithKline, Merck & Co, Inc, Monogram Biosciences, Inc, Pfizer Inc, Progenics Pharmaceuticals, Inc, Tibotec Therapeutics, and Tobira Therapeutics. He has received honoraria from Merck & Co, Inc, Pain Therapeutics, Inc, and Pfizer, Inc. (Updated 06/06/10)

Dr Sulkowski has received grants and research support from Abbott Laboratories, Boehringer Ingelheim Pharmaceutical, Inc, Genentech, Inc, Gilead Sciences, Inc, Merck & Co, Inc, Tibotec Therapeutics, Vertex Pharmaceuticals, Inc, and ZymoGenetics. He has served as a scientific advisor for Abbott Laboratories, Anadys Pharmaceuticals, Inc, Boehringer Ingelheim Pharmaceuticals, Inc, Gilead Sciences, Inc, Merck & Co, Inc, Pfizer, Inc, Roche/Genentech, Tibotec Therapeutics, and Vertex Pharmaceuticals, Inc. (Updated 05/19/10)


IAS–USA CME Staff

Ms Jacobsen has no relevant financial affiliations to disclose.


Grant Support

This Webcast activity is sponsored by the International AIDS Society–USA and funded by the International AIDS Society–USA.

Funding for the live activity, upon which this activity was based came from the following commercial companies:

Substantial Grants from:
Merck & Co, Inc
Tibotec Therapeutics

Bristol-Myers Squibb
Gilead Sciences, Inc

Generous Grants from:
ViiV Healthcare


Discussion of Investigational or Unapproved Usage

This activity presents an update on new research that may involve the use of investigational or unapproved drugs and therapies. Participants should consult the product information and other resources for comprehensive information on drugs and therapies discussed in the cases. The views and opinions expressed herein are those of the faculty and do not necessarily represent the opinions or recommendations of the International AIDS Society–USA.


Contact Information

If you have any questions about this Web-based CME conference activity, please contact the International AIDS Society–USA:

International AIDS Society–USA
425 California Street
Suite 1450
San Francisco, CA 94104-2120
Telephone: 415-544-9400
Fax: 415-544-9401
E-mail: registration2010@iasusa.org

I have read these instructions and understand them.